Cantargia, BioWa extend ongoing collaboration around POTELLIGENT technology

Image: Cantargia and BioWa have signed an extension of licence agreement around the BioWa POTELLIGENT technology to produce Cantargia’s antibody drug candidate CAN04. Photo: courtesy of Frauke Feind from Pixabay.